Cargando…
Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer
BACKGROUND: Epithelial splicing regulatory protein 1 (ESRP1) and 2 (ESRP2) regulate alternative splicing events of various pre-mRNAs. Some of these targets play a role in cancer-associated processes, including cytoskeleton reorganization and DNA-repair processes. This study was undertaken to estimat...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749503/ https://www.ncbi.nlm.nih.gov/pubmed/33339518 http://dx.doi.org/10.1186/s12885-020-07682-8 |
_version_ | 1783625316806164480 |
---|---|
author | Freytag, Morton Kluth, Martina Bady, Elena Hube-Magg, Claudia Makrypidi-Fraune, Georgia Heinzer, Hans Höflmayer, Doris Weidemann, Sören Uhlig, Ria Huland, Hartwig Graefen, Markus Bernreuther, Christian Wittmer, Corinna Tsourlakis, Maria Christina Minner, Sarah Dum, David Hinsch, Andrea Luebke, Andreas M. Simon, Ronald Sauter, Guido Schlomm, Thorsten Möller, Katharina |
author_facet | Freytag, Morton Kluth, Martina Bady, Elena Hube-Magg, Claudia Makrypidi-Fraune, Georgia Heinzer, Hans Höflmayer, Doris Weidemann, Sören Uhlig, Ria Huland, Hartwig Graefen, Markus Bernreuther, Christian Wittmer, Corinna Tsourlakis, Maria Christina Minner, Sarah Dum, David Hinsch, Andrea Luebke, Andreas M. Simon, Ronald Sauter, Guido Schlomm, Thorsten Möller, Katharina |
author_sort | Freytag, Morton |
collection | PubMed |
description | BACKGROUND: Epithelial splicing regulatory protein 1 (ESRP1) and 2 (ESRP2) regulate alternative splicing events of various pre-mRNAs. Some of these targets play a role in cancer-associated processes, including cytoskeleton reorganization and DNA-repair processes. This study was undertaken to estimate the impact of ESRP1 and ESRP2 alterations on prostate cancer patient prognosis. METHODS: A tissue microarray made from 17,747 individual cancer samples with comprehensive, pathological, clinical and molecular data was analyzed by immunohistochemistry for ESRP1 and ESRP2. RESULTS: Nuclear staining for ESRP1 was seen in 38.6% (36.0% low, 2.6% high) of 12,140 interpretable cancers and in 41.9% (36.4% low, 5.3% high) of 12,962 interpretable cancers for ESRP2. Nuclear protein expression was linked to advanced tumor stage, high Gleason score, presence of lymph node metastasis, early biochemical recurrence, and ERG-positive cancers (p < 0.0001 each). Expression of ESRPs was significantly linked to 11 (ESRP1)/9 (ESRP2) of 11 analyzed deletions in all cancers and to 8 (ESRP1)/9 (ESRP2) of 11 deletions in ERG-negative cancers portending a link to genomic instability. Combined ESRPs expression analysis suggested an additive effect and showed the worst prognosis for cancers with high ESRP1 and ESRP2 expression. Multivariate analyses revealed that the prognostic impact of ESRP1, ESRP2 and combined ESRP1/ESRP2 expression was independent of all established pre- and postoperative prognostic features. CONCLUSIONS: Our data show a striking link between nuclear ESRP expression and adverse features in prostate cancer and identifies expression of ESRP1 and/or ESRP2 as independent prognostic markers with a potential for routine application. |
format | Online Article Text |
id | pubmed-7749503 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77495032020-12-21 Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer Freytag, Morton Kluth, Martina Bady, Elena Hube-Magg, Claudia Makrypidi-Fraune, Georgia Heinzer, Hans Höflmayer, Doris Weidemann, Sören Uhlig, Ria Huland, Hartwig Graefen, Markus Bernreuther, Christian Wittmer, Corinna Tsourlakis, Maria Christina Minner, Sarah Dum, David Hinsch, Andrea Luebke, Andreas M. Simon, Ronald Sauter, Guido Schlomm, Thorsten Möller, Katharina BMC Cancer Research Article BACKGROUND: Epithelial splicing regulatory protein 1 (ESRP1) and 2 (ESRP2) regulate alternative splicing events of various pre-mRNAs. Some of these targets play a role in cancer-associated processes, including cytoskeleton reorganization and DNA-repair processes. This study was undertaken to estimate the impact of ESRP1 and ESRP2 alterations on prostate cancer patient prognosis. METHODS: A tissue microarray made from 17,747 individual cancer samples with comprehensive, pathological, clinical and molecular data was analyzed by immunohistochemistry for ESRP1 and ESRP2. RESULTS: Nuclear staining for ESRP1 was seen in 38.6% (36.0% low, 2.6% high) of 12,140 interpretable cancers and in 41.9% (36.4% low, 5.3% high) of 12,962 interpretable cancers for ESRP2. Nuclear protein expression was linked to advanced tumor stage, high Gleason score, presence of lymph node metastasis, early biochemical recurrence, and ERG-positive cancers (p < 0.0001 each). Expression of ESRPs was significantly linked to 11 (ESRP1)/9 (ESRP2) of 11 analyzed deletions in all cancers and to 8 (ESRP1)/9 (ESRP2) of 11 deletions in ERG-negative cancers portending a link to genomic instability. Combined ESRPs expression analysis suggested an additive effect and showed the worst prognosis for cancers with high ESRP1 and ESRP2 expression. Multivariate analyses revealed that the prognostic impact of ESRP1, ESRP2 and combined ESRP1/ESRP2 expression was independent of all established pre- and postoperative prognostic features. CONCLUSIONS: Our data show a striking link between nuclear ESRP expression and adverse features in prostate cancer and identifies expression of ESRP1 and/or ESRP2 as independent prognostic markers with a potential for routine application. BioMed Central 2020-12-18 /pmc/articles/PMC7749503/ /pubmed/33339518 http://dx.doi.org/10.1186/s12885-020-07682-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Freytag, Morton Kluth, Martina Bady, Elena Hube-Magg, Claudia Makrypidi-Fraune, Georgia Heinzer, Hans Höflmayer, Doris Weidemann, Sören Uhlig, Ria Huland, Hartwig Graefen, Markus Bernreuther, Christian Wittmer, Corinna Tsourlakis, Maria Christina Minner, Sarah Dum, David Hinsch, Andrea Luebke, Andreas M. Simon, Ronald Sauter, Guido Schlomm, Thorsten Möller, Katharina Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer |
title | Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer |
title_full | Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer |
title_fullStr | Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer |
title_full_unstemmed | Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer |
title_short | Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer |
title_sort | epithelial splicing regulatory protein 1 and 2 (esrp1 and esrp2) upregulation predicts poor prognosis in prostate cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749503/ https://www.ncbi.nlm.nih.gov/pubmed/33339518 http://dx.doi.org/10.1186/s12885-020-07682-8 |
work_keys_str_mv | AT freytagmorton epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT kluthmartina epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT badyelena epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT hubemaggclaudia epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT makrypidifraunegeorgia epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT heinzerhans epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT hoflmayerdoris epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT weidemannsoren epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT uhligria epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT hulandhartwig epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT graefenmarkus epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT bernreutherchristian epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT wittmercorinna epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT tsourlakismariachristina epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT minnersarah epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT dumdavid epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT hinschandrea epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT luebkeandreasm epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT simonronald epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT sauterguido epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT schlommthorsten epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer AT mollerkatharina epithelialsplicingregulatoryprotein1and2esrp1andesrp2upregulationpredictspoorprognosisinprostatecancer |